Skip to main content
Top
Published in: Diabetologia 8/2009

Open Access 01-08-2009 | Research Letter

Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births

Authors: A. S. Slingerland, B. M. Shields, S. E. Flanagan, G. J. Bruining, K. Noordam, A. Gach, W. Mlynarski, M. T. Malecki, A. T. Hattersley, S. Ellard

Published in: Diabetologia | Issue 8/2009

Login to get access

Excerpt

To the Editor: Surveys of neonatal diabetes in the UK and Germany from more than a decade ago reported an incidence of 1 in 400,000–450,000 live births [1, 2]. The permanent form of neonatal diabetes mellitus (PNDM) accounted for about half the cases, equating to a PNDM incidence of 1 in 800,000–900,000 live births. The definition of neonatal diabetes used in these publications was a diagnosis of diabetes within 4 weeks [1] or 6 weeks [2] of birth. HLA genotype analysis has shown that permanent diabetes diagnosed within the first 6 months of life is PNDM rather than type 1 diabetes [3]. Using a definition of diagnosis before 6 months, the incidence of PNDM was recently calculated at 1 in 214,000 live births from the Slovakian diabetes register [4]. We examined the incidence rates of PNDM in three further European countries. …
Literature
1.
go back to reference von Mühlendahl KE, Herkenhoff H (1995) Long-term course of neonatal diabetes. N Engl J Med 333:704–708CrossRef von Mühlendahl KE, Herkenhoff H (1995) Long-term course of neonatal diabetes. N Engl J Med 333:704–708CrossRef
2.
go back to reference Shield JPH, Gardner RJ, Wadsworth EJK et al (1997) Aetiopathology and genetic basis of neonatal diabetes. Arch Dis Child 76:F39–F42 Shield JPH, Gardner RJ, Wadsworth EJK et al (1997) Aetiopathology and genetic basis of neonatal diabetes. Arch Dis Child 76:F39–F42
3.
go back to reference Edghill EL, Dix RJ, Flanagan SE et al (2006) HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes 55:1895–1898PubMedCrossRef Edghill EL, Dix RJ, Flanagan SE et al (2006) HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes 55:1895–1898PubMedCrossRef
4.
go back to reference Stanik J, Gasperikova D, Paskova M et al (2007) Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab 92:1276–1282PubMedCrossRef Stanik J, Gasperikova D, Paskova M et al (2007) Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab 92:1276–1282PubMedCrossRef
5.
go back to reference Gloyn AL, Pearson ER, Antcliff JF et al (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350:1838–1849PubMedCrossRef Gloyn AL, Pearson ER, Antcliff JF et al (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350:1838–1849PubMedCrossRef
6.
go back to reference Bappal B, Raghupathy P, de Silva V, Khusaiby SM (1999) Permanent neonatal diabetes mellitus: clinical presentation and epidemiology in Oman. Arch Dis Child Fetal Neonatal Ed 80:F209–F212PubMedCrossRef Bappal B, Raghupathy P, de Silva V, Khusaiby SM (1999) Permanent neonatal diabetes mellitus: clinical presentation and epidemiology in Oman. Arch Dis Child Fetal Neonatal Ed 80:F209–F212PubMedCrossRef
7.
go back to reference Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT (2006) Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 49:1190–1197PubMedCrossRef Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT (2006) Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 49:1190–1197PubMedCrossRef
8.
go back to reference Pearson ER, Flechtner I, Njolstad PR et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467–477PubMedCrossRef Pearson ER, Flechtner I, Njolstad PR et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467–477PubMedCrossRef
9.
go back to reference Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT (2007) Effective treatment with oral sulfonylureas in patients with diabetes due to SUR1 mutations. Diabetes Care 31:204–209PubMedCrossRef Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT (2007) Effective treatment with oral sulfonylureas in patients with diabetes due to SUR1 mutations. Diabetes Care 31:204–209PubMedCrossRef
Metadata
Title
Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births
Authors
A. S. Slingerland
B. M. Shields
S. E. Flanagan
G. J. Bruining
K. Noordam
A. Gach
W. Mlynarski
M. T. Malecki
A. T. Hattersley
S. Ellard
Publication date
01-08-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1416-6

Other articles of this Issue 8/2009

Diabetologia 8/2009 Go to the issue